XM no presta servicios a los residentes de Estados Unidos de América.

XM no presta servicios a los residentes de Estados Unidos de América.
S
S

Stryker

Noticias

Reuters - Hace 1 semana

Zimmer Biomet beats profit estimates on strong demand for medical devices

Zimmer Biomet beats profit estimates on strong demand for medical devices Aug 7 (Reuters) - Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures. Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
S
Z
Reuters - Hace 1 semana

Baxter raises full-year profit forecast on robust demand for medical devices

Baxter raises full-year profit forecast on robust demand for medical devices Aug 6 (Reuters) - Baxter International BAX.N on Tuesday raised its annual profit expectations and beat Wall Street estimates for second-quarter profit on strong sales of its medical devices, driven by robust demand for medical care among patients. Shares of the company rose 3% to $35.69 in premarket trading.
S
Reuters - Hace 2 semanas

Teleflex raises 2024 profit forecast on medical device demand

Teleflex raises 2024 profit forecast on medical device demand Aug 1 (Reuters) - Surgical equipment maker Teleflex TFX.N raised its annual profit forecast on Thursday, banking on resilient demand for certain surgical procedures at hospitals to drive sales for its medical devices. The company also said its board authorized a share repurchase program for up to $500 million of common stock.
S
T
Reuters - Hace 2 semanas

Stryker beats Q2 profit estimates on robust demand for medical devices, implants

Stryker beats Q2 profit estimates on robust demand for medical devices, implants July 30 (Reuters) - Stryker Corp SYK.N posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries. On an adjusted basis, the company reported a profit of $2.81 per share for the quarter ended June 30, slightly above analysts' estimates of $2.79 per share.
S
Reuters - Hace 2 semanas

Stryker Q2 Adjusted EPS USD 2.81 Vs. IBES Estimate USD 2.79

BRIEF-Stryker Q2 Adjusted EPS USD 2.81 Vs. IBES Estimate USD 2.79 Jul 30 (Reuters) - Stryker Q2 adjusted EBIT margin 24.6%. Q2 EPS USD 2.14 Q2 revenue USD 5,400 million vs. IBES estimate USD 5,406 million Q2 adjusted net income USD 1,085 million vs. IBES estimate USD 1,072 million Q2 adjusted gross margin 64.2% Q2 net income USD 825 million outlook
S
Reuters - Hace 2 semanas

Microsoft and job openings to hit pre-Fed vigil

MORNING BID AMERICAS-Microsoft and job openings to hit pre-Fed vigil A look at the day ahead in U.S. and global markets from Mike Dolan To the extent that worries about pricey tech stocks and rising AI capex spending were partly behind last week's market shakeout, Microsoft's quarterly update should prove a key moment later on Tuesday, just as the Federal Reserve's latest policy meeting gets under way.
A
A
E
G
I
M
M
N
P
S
U
A
G
J
U
U
U
F
E
E
S
A
H
L
Reuters - Hace 3 semanas

Stryker Corp <SYK.N> expected to post earnings of $2.79 a share - Earnings Preview

Stryker Corp expected to post earnings of $2.79 a share - Earnings Preview Stryker Corp SYK.N , SYK is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Portage Michigan-based company is expected to report a 8.2% increase in revenue to $5.406 billion from $5 billion a year ago, according to the mean estimate from 24 analysts, based on LSEG data.
S
Reuters - Hace 4 semanas

Some medical device makers rise, while others tip lower after J&J results

BUZZ-Some medical device makers rise, while others tip lower after J&J results ** Some medical device manufacturers rise after Johnson & Johnson's JNJ.N results, while others fall ** Zimmer Biomet ZBH.N rise 2.9% to $110.58, Medtronic MDT.N gain 2.45% to $80.01, Abbott ABT.N rise 2.10% to $104.90, Stryker SYK.N up 1.04% at $336.90 ** Shares of Intu
A
C
S
Z
Reuters - Hace 4 semanas

J&J beats Wall St estimates on strong drug sales ahead of Stelara competition

CORRECTED-UPDATE 3-J&J beats Wall St estimates on strong drug sales ahead of Stelara competition Corrects paragraph 4 as J&J CFO did not suggest pending Stelara insurance contracts would be 'favorable' By Patrick Wingrove and Bhanvi Satija July 17 (Reuters) - Johnson & Johnson JNJ.N beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara .
A
S
Reuters - Hace 4 semanas

Stryker Completes Acquisition Of Artelon

BRIEF-Stryker Completes Acquisition Of Artelon July 15 (Reuters) - Stryker Corp SYK.N : STRYKER COMPLETES ACQUISITION OF ARTELON, INC. Source text for Eikon: ID:nBw2Q55RHa Further company coverage: SYK.N
S
Reuters - Hace 1 mes

Smith & Nephew faces long and painful activist fix

BREAKINGVIEWS-Smith & Nephew faces long and painful activist fix The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 4 (Reuters Breakingviews) - Smith & Nephew SN.L should prepare for a long and painful activist treatment. On Thursday, Swedish investor Cevian Capital announced it had taken a 5% stake in the $11 billion UK-listed maker of hip joints and wound care kit.
U
S
Reuters - Hace 2 meses

Masimo COO Muhsin to resign if activist investor Politan takes control

UPDATE 2-Masimo COO Muhsin to resign if activist investor Politan takes control Adds background throughout July 1 (Reuters) - Masimo MASI.O Chief Operating Officer Bilal Muhsin has told the board he would resign if activist investor Politan Capital Management takes control of the company and CEO Joe Kiani is removed, according to a regulatory filing.
A
S

Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.